SCOPUS 정보 검색 플랫폼

Volumn 120, Issue 5, 2013, Pages 1057-1063

Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography

(4) Bhisitkul, Robert B a Campochiaro, Peter A b Shapiro, Howard c Rubio, Roman G c

a UNIVERSITY OF CALIFORNIA (United States)

b JOHNS HOPKINS UNIVERSITY (United States)

c GENENTECH INC (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ARTICLE; BRANCH RETINAL VEIN OCCLUSION; FOLLOW UP; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MEASUREMENT; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RETINA FOVEA; RETINA MACULA CYSTOID EDEMA; SUBRETINAL FLUID; TREATMENT RESPONSE; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; MACULAR EDEMA; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84877763395 PISSN: 01616420 EISSN: 15494713 Source Type: Journal
DOI: 10.1016/j.ophtha.2012.11.011 Document Type: Article

Times cited : (71)

References (6)

1
- 41149085598
- Ranibizumab for macular edema due to retinal vein occlusions: Implication of VEGF as a critical stimulator
- DOI 10.1038/mt.2008.10, PII MT200810
- P.A. Campochiaro, G. Hafiz, S.M. Shah Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator Mol Ther 16 2008 791 799 (Pubitemid 351426182)
- (2008) Molecular Therapy , vol.16 , Issue.4 , pp. 791-799
- Campochiaro, P.A.¹ Hafiz, G.² Shah, S.M.³ Nguyen, Q.D.⁴ Ying, H.⁵ Do, D.V.⁶ Quinlan, E.⁷ Zimmer-Galler, I.⁸ Haller, J.A.⁹ Solomon, S.D.¹⁰ Sung, J.U.¹¹ Hadi, Y.¹² Janjua, K.A.¹³ Jawed, N.¹⁴ Choy, D.F.¹⁵ Arron, J.R.¹⁶

2
- 77952891051
- Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase III study
- BRAVO Investigators
- P.A. Campochiaro, J.S. Heier, L. Feiner BRAVO Investigators Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 2010 1102 1112
- (2010) Ophthalmology , vol.117 , pp. 1102-1112
- Campochiaro, P.A.¹ Heier, J.S.² Feiner, L.³

3
- 77952889477
- Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study
- CRUISE Investigators
- D.M. Brown, P.A. Campochiaro, R.P. Singh CRUISE Investigators Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 2010 1124 1133
- (2010) Ophthalmology , vol.117 , pp. 1124-1133
- Brown, D.M.¹ Campochiaro, P.A.² Singh, R.P.³

4
- 79958817527
- Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study
- D.M. Brown, P.A. Campochiaro, R.B. Bhisitkul Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study Ophthalmology 118 2011 1594 1602
- (2011) Ophthalmology , vol.118 , pp. 1594-1602
- Brown, D.M.¹ Campochiaro, P.A.² Bhisitkul, R.B.³

5
- 79958843614
- Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve-month outcomes of a phase III study
- P.A. Campochiaro, D.M. Brown, C.C. Awh Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study Ophthalmology 118 2011 2041 2049
- (2011) Ophthalmology , vol.118 , pp. 2041-2049
- Campochiaro, P.A.¹ Brown, D.M.² Awh, C.C.³

6
- 84862817252
- Ranibizumab for macular edema due to retinal vein occlusions: Long-term follow-up in the HORIZON trial
- J.S. Heier, P.A. Campochiaro, L. Yau Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial Ophthalmology 119 2012 802 809
- (2012) Ophthalmology , vol.119 , pp. 802-809
- Heier, J.S.¹ Campochiaro, P.A.² Yau, L.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.